top of page
LogoWix.jpg
Search

Regenerative Research Roundup - September 2026

jtomkin3
Sep 3
3 min read

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in quick-to-read digest.


This month, we explore:

  • Comparing the clinical efficacy of PRP and Hyaluronic acid in knee OA

  • PRP + HA combination therapy showing improved pain and function up to 24 post injection

  • The effects of a high-molecular weight and linear HA on synovial fluid and joint environment

  • Comparing year-long outcomes outcomes with leukocyte-rich, leukocyte-poor and PRF to corticosteroids


Let's dive in!


Beyond Symptom Relief: PRP Versus Hyaluronic Acid for Knee Osteoarthritis: An Ambispective Comparative Cohort Study


CME Journal of Geriatric Medicine // LOE: III


An ambispective observational study comparing the clinical efficacy and safety of intra-articular platelet-rich plasma (PRP) with hyaluronic acid (HA) in patients with KL grade I-III knee OA.  Patients received either leukocyte-poor PRP (n=102) or HA (n=102), and clinical outcomes were assessed using the WOMAC, VAS and IKDC scores over 12 months.

 

Key Findings:

  • Both PRP and HA demonstrated fast-acting early relief, showing statistically significant decrease in WOMAC and VAS pain scores by month 1

  • PRP demonstrated greater treatment durability and symptom relief compared to HA, with sustained improvement lasting up to a year – exceeding the MCID on both WOMAC and VAS scores.

  • At 12 months, functional improvements with both treatments were greater in mild-to-moderate disease compared to moderate-to-severe

 

Clinical Perspective:

 

Another confirmatory study showcasing the durability of PRP treatment compared to HA, with greater overall long-term improvement across pain and composite scoring.  Interestingly, the PRP system used was the GPS III, with a 35ml blood draw, and administering roughly 4-5 billion platelets per injection – coming in at half the dosing target established for knee OA - yet still exceeding the MCID of a 10-12 difference in WOMAC pain points.


These findings can infer that with a higher dose PRP system, exceeding by a full MCID is reasonably achievable.

 



Improving the Efficacy of Hyaluronic Acid Injections: A Narrative Review of Combined Hyaluronic Acid and Platelet-Rich Plasma for Knee Osteoarthritis


JBJS Journal of Orthopaedics for Physician Assistants // LOE: V


A narrative review conducted using the PubMed, Embase and ATSU library comparing the efficacy of HA + PRP combination therapy with HA + corticosteroids (CS) and HA monotherapy, in terms of improving clinical outcomes in knee OA.

 

Key Findings:

  • HA + PRP combination introduces growth factors that support chondral preservation and improved pain and function up to 24 months

  • The HA + CS combination provides pain relief as early as 24-72 hours

  • Earlier intervention generally provides greater treatment benefit

 

Clinical Perspective:

 

Successful OA management rarely depends on a single intervention alone. While many treatments earn their place in a regenerative portfolio, the HA+PRP combination remains the current standard for long-term knee OA management.




Effects of Intra-Articular Administration of High-Molecular-Weight Linear Hyaluronic Acid on Synovial Fluid Characteristics and Joint Environment



Antioxidants // LOE: Preclinical


A randomized pre-clinical study evaluating the effect of a high-molecular weight, non-chemically crosslinked HA following induced synovitis in 16 horses. 


Key Finding:

  • HMW HA was associated with faster improvement in lameness and reduced early synovial membrane thickening

  • HMW HA significantly reduced lipid peroxidation, supporting a role in moderating oxidative stress within the inflamed joint

 

Clinical Perspective:


This study reinforces the mechanistic support that linear high-molecular-weight hyaluronic acid may influence the joint environment beyond simply restoring viscosity. While these findings are pre-clinical, the observed reduction in oxidative stress and early synovial membrane changes provide additional biologic rationale for utilizing HA as part of a comprehensive joint preservation strategy.

 



Comparative Outcome Analysis of Leukocyte-Rich Platelet-rich Plasma, Leukocyte-Poor Platelet-rich Plasma, Injectable Platelet-rich Fibrin and Corticosteroid Injections in Periarthritis of the Shoulder


Journal of Orthopaedic Case Reports // LOE: II


A double-blinded four-arm randomized controlled trial evaluating leukocyte-poor PRP, leukocyte-rich PRP, injectable platelet-rich fibrin (iPRF), and corticosteroid injections for periarthritis of the shoulder.  64 patients were followed for 12 months using VAS and DASH outcome measures.


Key Findings:

  • Corticosteroids had the largest treatment effect at month 1, and quickly tapered off

  • All PRP groups, showed statistically significant reduction in VAS pain scores and DASH outcomes sustained up to 12 months

Figure 1. Mean Visual Analog Scale pain scores across follow-up by treatment group.


Clinical Perspective:

 

While corticosteroids delivered the fastest early relief, platelet concentrates demonstrated superior durability at 12 months.  These findings further support the long-term value of regenerative therapies while highlighting the clinical impact of PRP formulation.


 
 
 

Comments

bottom of page